Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland
Authors
Keywords
Multiple sclerosis, Lesions, Magnetic resonance imaging, Switzerland, Yeast infections, B cells, Observational studies, White blood cells
Journal
PLoS One
Volume 13, Issue 5, Pages e0197415
Publisher
Public Library of Science (PLoS)
Online
2018-05-15
DOI
10.1371/journal.pone.0197415
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multiple Sclerosis
- (2018) Daniel S. Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
- (2017) Tomas Kalincik et al. LANCET NEUROLOGY
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice
- (2017) Hjalmar Wadström et al. JAMA Internal Medicine
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
- (2016) Peter Alping et al. ANNALS OF NEUROLOGY
- Disease activity return after natalizumab cessation in multiple sclerosis
- (2016) Maria Rasenack et al. Expert Review of Neurotherapeutics
- MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
- (2016) Massimo Filippi et al. LANCET NEUROLOGY
- Rituximab in multiple sclerosis
- (2016) Jonatan Salzer et al. NEUROLOGY
- Disease activity return after natalizumab cessation in multiple sclerosis
- (2016) Maria Rasenack et al. Expert Review of Neurotherapeutics
- Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients
- (2014) Per Soelberg Sorensen et al. JOURNAL OF NEUROLOGY
- Glatiramer Acetate in the Treatment of Multiple Sclerosis
- (2011) Patrice H. Lalive et al. CNS DRUGS
- Comparative study of mitoxantrone efficacy profile in patients with relapsing—remitting and secondary progressive multiple sclerosis
- (2010) Federica Esposito et al. Multiple Sclerosis Journal
- Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
- (2010) R. T. Naismith et al. NEUROLOGY
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab
- (2008) Roy M. Fleischmann SEMINARS IN ARTHRITIS AND RHEUMATISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started